Medicine Pricing: Where Must Profit Stop?

When a family receives a serious medical diagnosis, the immediate concern is securing treatment. A caregiver searches for the prescribed medicine, arranges the money and pays the price demanded. Fear, urgency and the hope of recovery leave little room to question the bill or investigate who profits along the way.

This vulnerability creates a profound imbalance. Patients often have limited information and little bargaining power, while commercial participants across the pharmaceutical value chain understand the economics of the products they sell. The patient sees the final price. The distribution of earnings, incentives and payments behind it remains largely invisible.

• 
  NDTV Profit Ignite 2026 Live Updates: Tamannaah Bhatia Opens Up On Acting And Business
• 
  Gold Price Dips Ahead Of Diwali: Can It Go Lower On Dhanteras? What To Expect
• 
  What Would Make Brokers Bullish Again On Indian Markets? Axis Lists Its Triggers
• 
  India's Market Leaders To Decode The New Samvat At NDTV Profit Ignite In Mumbai On Oct 28
• 
  NDTV Profit IGNITE Diwali 2026: Top Market Veterans Decode Wealth Creation
• 
  NDTV Ignite, The Trillion-Dollar Trajectory: India's Road to 2030

The Supreme Court's recent scrutiny of medicine trade margins has brought this imbalance into focus. The debate raises a question for policymakers and the industry alike: how should India distinguish legitimate commercial returns from excessive margins, particularly when patients have limited alternatives?

Healthcare and pharmaceuticals are commercial sectors. Research, manufacturing, quality assurance and distribution require investment, and businesses must earn viable returns. The difficult question is where reasonable profitability ends and disproportionate extraction begins.

When Do Profits Become Excessive?

Consider the reported example of a cancer medicine supplied to a retailer for around ₹2,700 while carrying a maximum retail price of approximately ₹27,000. The difference warrants scrutiny, although it does not, by itself, establish the actual profit earned by each participant or account for every cost incurred. It does demand a credible explanation of how the final price was determined.

Every participant in the supply chain may deserve compensation for a legitimate contribution. The concern arises when successive margins inflate the price beyond what the economics of the product and its distribution can reasonably justify. A patient's willingness to pay cannot be treated as proof of a fair price when the purchase is driven by medical necessity.

The Reserve Bank of India's concern with usurious interest rates offers a useful parallel. Lending is a legitimate business, but returns and terms can warrant intervention when vulnerable borrowers face exploitative conditions. Medicine pricing requires its own evidence-based benchmarks, reflecting differences in manufacturing costs, distribution, research and market competition. The regulatory objective should be to identify disproportionate margins without undermining legitimate investment or supply.

The greed of participants who exploit patient and caregiver distress deserves particular attention. When a family is confronting a life-threatening illness, the urgency of treatment can become a commercial advantage for those positioned to extract excessive returns. That possibility makes transparency essential.

Also Read: When Everyone Has AI, What Gives You An Edge?

Follow The Money Across The Chain

India has a medicine price-control framework administered by the National Pharmaceutical Pricing Authority under the Drugs (Prices Control) Order, 2013. The immediate regulatory need is to establish whether authorities have sufficient information to understand how prices are formed and how commercial incentives influence transactions across the value chain.

The government should require relevant manufacturers, distributors and other participants to disclose defined categories of trade margins, distribution fees, promotional expenditure, incentives and payments connected with medicine marketing. Common reporting standards, auditable records and independent verification would allow regulators to trace financial flows and investigate unusual pricing patterns. Commercial confidentiality should not prevent access to information necessary for public-interest regulation.

The issue becomes more serious when payments influence prescribing. Improper inducements offered to secure a doctor's preference for a particular medicine can compromise clinical independence and distort competition. Patients generally assume that a prescription reflects medical judgement, with little ability to establish whether undisclosed commercial considerations have influenced the recommendation.

Allegations must be established through evidence, without casting suspicion on the medical profession as a whole. However, professional standing cannot shield proven misconduct. Regulations should require appropriate disclosure of relevant payments, enable investigation of suspicious transactions and impose credible penalties for concealed benefits or proven inducements.

These obligations must be enforceable. Regulators need the authority, information and capacity to examine payment arrangements, identify conflicts of interest and act against violations. Without that visibility, the system risks leaving the most consequential commercial relationships beyond effective scrutiny.

Medicine Demands An Ethical Standard

The pharmaceutical industry also needs a fair regulatory environment. Research and development involve risk, manufacturing requires investment, and specialised medicines may carry substantial costs. Poorly designed price controls can discourage investment, make some products commercially unattractive or threaten availability. A widely used generic and a patented therapy may have very different economics, so regulatory intervention must reflect evidence rather than assume that one margin fits every medicine.

Yet commercial viability cannot excuse excessive mark-ups or improper inducements. Medicines are purchased under circumstances in which fear, distress and hope shape decisions. The integrity of the industry depends on how products are priced, how commercial relationships operate and whether prescribing remains independent of financial influence.

This is now a question of ethics and integrity across the pharmaceutical and healthcare ecosystem. Government must establish clear disclosure requirements, regulators must enforce them consistently, and businesses must account for the commercial arrangements through which they earn their returns. The impact of reform should be assessed through patient affordability, the availability of quality medicines and the sustainability of supply.

The principle is straightforward: legitimate profit deserves protection, while excessive margins and corrupt incentives demand scrutiny. An industry entrusted with human health must be able to demonstrate that its commercial conduct meets the ethical responsibility that comes with that trust.

Disclaimer: The views expressed in this article are solely those of the author and do not necessarily reflect the opinion of NDTV Profit or its affiliates. Readers are advised to conduct their own research or consult a qualified professional before making any investment or business decisions. NDTV Profit does not guarantee the accuracy, completeness, or reliability of the information presented in this article.

Also Read: You May Inherit The Business. You Must Earn Its Credibility.

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.